Long-term follow up of older people on diabetes medications: observational study using linked health databases
Katharine A. Wallis
A B C , Susan Wells A , Vanessa Selak A and Katrina Poppe A
+ Author Affiliations
- Author Affiliations
A The University of Auckland, Private Bag 92019, Auckland 1023, New Zealand.
B Primary Care Clinical Unit, Faculty of Medicine, The University of Queensland, UQ Health Sciences Building, Herston, Qld 4029, Australia.
C Corresponding author. Email: k.wallis@uq.edu.au
Australian Journal of Primary Health 26(4) 306-312 https://doi.org/10.1071/PY19246
Submitted: 17 December 2019 Accepted: 13 May 2020 Published: 30 June 2020
Abstract
There is uncertainty about the long-term benefits and risks of diabetes medications in older people. We investigated differences in hypoglycaemia, cardiovascular disease (CVD) or mortality in older people according to diabetes medication, using linked national hospitalisation and mortality data from New Zealand. Adults aged ≥65 years dispensed diabetes medication in 2010 with a baseline glycated haemoglobulin (HbA1c) level (n = 18 099, mean age 73 years, 50% female) were included and stratified into four groups: metformin-only (42%); metformin-plus-other-oral-hypoglycaemic/s (27%); other-oral/s-only (11%); and any-insulin (20%). Time to first event was analysed with Cox models adjusted for sociodemographic factors; clinical history (prior hospitalisation for diabetes or CVD, and comorbidities); glycated haemoglobin; and CVD medications. Over 7-year follow up, 16% of participants experienced hypoglycaemia, 36% a CVD event and 31% died. Compared with metformin-only, insulin and other oral hypoglycaemic/s were associated with five- to 10-fold long-term increased risk of hypoglycaemia, and increased risk of CVD and death although adjusted survival curves showed no important separation between medication groups for CVD and death with the possible exception of insulin. Although confounding by indication is unable to be eliminated, this study raises further questions about the use of second-line diabetes medications in older people.
Additional keywords: disease management, health services: aged, medication therapy management, primary health care.
References
Arnold SV, Lipska KJ, Wang J, Seman L, Mehta SN, Kosiborod M (2018) Use of intensive glycemic management in older adults with diabetes mellitus. Journal of the American Geriatrics Society 66, 1190–1194.| Use of intensive glycemic management in older adults with diabetes mellitus.Crossref | GoogleScholarGoogle Scholar | 29633237PubMed |
Atkinson J, Salmond C, Crampton P (2014) NZDep2013 Index of Deprivation. Department of Public Health, University of Otago, Wellington, New Zealand.
Bannister CA, Holden SE, Jenkins-Jones S, Morgan CL, Halcox JP, Schernthaner G, Mukherjee J, Currie CJ (2014) Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes, Obesity & Metabolism 16, 1165–1173.
| Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls.Crossref | GoogleScholarGoogle Scholar |
Black CD, Thompson W, Welch V, McCarthy L, Rojas-Fernandez C, Lochnan H, Shamji S, Upshur R, Farrell B (2017) Lack of evidence to guide deprescribing of antihyperglycemics: a systematic review. Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders 8, 23–31.
| Lack of evidence to guide deprescribing of antihyperglycemics: a systematic review.Crossref | GoogleScholarGoogle Scholar |
Bruce DG, Davis WA, Davis TME (2018) Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II. Diabetes, Obesity & Metabolism 20, 2852–2859.
| Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II.Crossref | GoogleScholarGoogle Scholar |
Charlson M, Szatrowski TP, Peterson J, Gold J (1994) Validation of a combined comorbidity index. Journal of Clinical Epidemiology 47, 1245–1251.
| Validation of a combined comorbidity index.Crossref | GoogleScholarGoogle Scholar | 7722560PubMed |
Christensen DH, Rungby J, Thomsen RW (2016) Nationwide trends in glucose-lowering drug use, Denmark, 1999–2014. Clinical Epidemiology 8, 381–387.
| Nationwide trends in glucose-lowering drug use, Denmark, 1999–2014.Crossref | GoogleScholarGoogle Scholar | 27789974PubMed |
Cruz-Jentoft AJ, Carpena-Ruiz M, Montero-Errasquín B, Sánchez-Castellano C, Sánchez-García E (2013) Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus. Journal of the American Geriatrics Society 61, 734–738.
| Exclusion of older adults from ongoing clinical trials about type 2 diabetes mellitus.Crossref | GoogleScholarGoogle Scholar | 23590338PubMed |
Goto A, Arah OA, Goto M, Terauchi Y, Noda M (2013) Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 347, f4533
| Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis.Crossref | GoogleScholarGoogle Scholar | 23900314PubMed |
Heald AH, Anderson SG, Cortes GJ, Cholakova V, Narajos M, Khan A, Donnahey G, Livingston M (2018) Hypoglycaemia in the over 75s: understanding the predisposing factors in type 2 diabetes (T2DM). Primary Care Diabetes 12, 133–138.
| Hypoglycaemia in the over 75s: understanding the predisposing factors in type 2 diabetes (T2DM).Crossref | GoogleScholarGoogle Scholar | 28941578PubMed |
Health Quality & Safety Commission New Zealand (2019) ‘Atlas of Healthcare Variation: Diabetes.’ (Health Quality & Safety Commission New Zealand: Wellington, New Zealand)
Huang ES, Laiteerapong N, Liu JY, John PM, Moffet HH, Karter AJ (2014) Rates of complications and mortality in older patients with diabetes mellitus: the diabetes and aging study. JAMA Internal Medicine 174, 251–258.
Lee AK, Warren B, Lee CJ, Huang ES, Sharrett AR, Coresh J, Selvin E (2017) Association of severe hypoglycemia with cardiovascular disease and all-cause mortality in older adults with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 135, A43
Lee AK, Warren B, Lee CJ, McEvoy JW, Matsushita K, Huang ES, Sharrett AR, Coresh J, Selvin E (2018) The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes. Diabetes Care 41, 104–111.
| The association of severe hypoglycemia with incident cardiovascular events and mortality in adults with type 2 diabetes.Crossref | GoogleScholarGoogle Scholar | 29127240PubMed |
Lipska KJ, Laiteerapong N (2019) Lack of glycemic legacy effects in the Veterans Affairs Diabetes Trial. The New England Journal of Medicine 380, 2266–2267.
| Lack of glycemic legacy effects in the Veterans Affairs Diabetes Trial.Crossref | GoogleScholarGoogle Scholar | 31167058PubMed |
Lipska KJ, Ross JS, Miao Y, Shah ND, Lee SJ, Steinman MA (2015) Potential overtreatment of diabetes mellitus in older adults with tight glycemic control. JAMA Internal Medicine 175, 356–362.
Lipska KJ, Krumholz H, Soones T, Lee SJ (2016) Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes. Journal of the American Medical Association 315, 1034–1045.
| Polypharmacy in the aging patient: a review of glycemic control in older adults with type 2 diabetes.Crossref | GoogleScholarGoogle Scholar | 26954412PubMed |
Luo M, Tan KHX, Tan CS, Lim WY, Tai E-S, Venkataraman K (2018) Longitudinal trends in HbA1c patterns and association with outcomes: a systematic review. Diabetes/Metabolism Research and Reviews 34, e3015
| Longitudinal trends in HbA1c patterns and association with outcomes: a systematic review.Crossref | GoogleScholarGoogle Scholar | 29663623PubMed |
Maciejewski ML, Mi X, Sussman J, Greiner M, Curtis LH, Ng J, Haffer SC, Kerr EA (2018) Overtreatment and deintensification of diabetic therapy among Medicare beneficiaries. Journal of General Internal Medicine 33, 34–41.
| Overtreatment and deintensification of diabetic therapy among Medicare beneficiaries.Crossref | GoogleScholarGoogle Scholar | 28905179PubMed |
McCoy RG, Lipska KJ, Yao X, Ross JS, Montori VM, Shah ND (2016) Intensive treatment and severe hypoglycemia among adults with type 2 diabetes. JAMA Internal Medicine 176, 969–978.
Miller ME, Williamson JD, Gerstein HC, Byington RP, Cushman WC, Ginsberg HN, Ambrosius WT, Lovato L, Applegate WB (2014) Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD trial. Diabetes Care 37, 634–643.
| Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD trial.Crossref | GoogleScholarGoogle Scholar | 24170759PubMed |
Ministry of Health (2009) National Health Index data dictionary. Version 5.3. Ministry of Health, Wellington, New Zealand.
Ministry of Health (2016a). Mortality and demographic data: mortality 2014 data tables. Ministry of Health, Wellington, New Zealand.
Ministry of Health (2016b) National minimum dataset (hospital events) data dictionary (version 7.8). Ministry of Health, Wellington, New Zealand.
Ministry of Health (2017) HISO 10001:2017 Ethnicity Data Protocols. Ministry of Health, Wellington, New Zealand.
Ministry of Health (2018) Pharmaceutical Collection. Ministry of Health, Wellington, New Zealand.
O’Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N, Moran MR, Liss DT, Prospect TA, Ackermann RT (2018) Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes. JAMA Network Open 1, e186125
R Core Team (2018) ‘R: a language and environment for statistical computing.’ (Foundation for Statistical Computing: Vienna, Austria)
Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, Duckworth WC, Hayward RA (2019) Intensive glucose control in patients with type 2 diabetes — 15-year follow-up. The New England Journal of Medicine 380, 2215–2224.
| Intensive glucose control in patients with type 2 diabetes — 15-year follow-up.Crossref | GoogleScholarGoogle Scholar | 31167051PubMed |
Statistics New Zealand (2013). 2013 Census QuickStats about a place.
Therneau T (2015). A package for survival analysis in S. version 2.38.
Tseng CL, Soroka O, Maney M, Aron DC, Pogach LM (2014) Assessing potential glycemic overtreatment in persons at hypoglycemic risk. JAMA Internal Medicine 174, 259–268.
UK Prospective Diabetes Study Group (UKPDS) (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352, 837–853.
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes.Crossref | GoogleScholarGoogle Scholar | 9742976PubMed |
Weiner JZ, Gopalan A, Mishra P, Lipska KJ, Huang ES, Laiteerapong N, Karter AJ, Grant RW (2019) Use and discontinuation of insulin treatment among adults aged 75 to 79 years with type 2 diabetes. JAMA Internal Medicine 179, 1633–1641.
Wells S, Kerr A, Pylypchuk R, Chelimo C, Marshall R, Exeter D, Mehta S, Harrison J, Kyle C, Grey C, Metcalf P, Warren J, Kenealy T, Drury P, Harwood H, Bramley D, Gala G, Jackson R (2017) Cohort profile: The PREDICT Cardiovascular Disease Cohort in New Zealand Primary Care (PREDICT-CVD 19). International Journal of Epidemiology 46, 22
